Tapinarof Cream 1% for Atopic Dermatitis
Tapinarof cream 1% applied once daily is safe and effective for both adults and children with atopic dermatitis, based on two phase 3 trials.
Study Overview
In the ADORING 1 and 2 trials, patients aged 2 years and older used Tapinarof or a placebo cream daily for 8 weeks. We focused on how well patients tolerated the cream.
Key Findings
- Participants: 813 patients, about 80% were children.
- Tolerability Scores:
- Patients reported slight burning/stinging and itching before treatment.
- Investigators noted minimal irritation.
- After 8 Weeks:
- Patients experienced very low levels of burning/stinging (0.2-0.4) and itching (0.6-0.8).
- Investigators observed minimal irritation with scores of 0.2 and 0.1 in the two trials.
- Sensitive Areas: No significant irritation was reported on sensitive skin areas throughout the study.
Conclusion
Tapinarof cream was well tolerated from the first application through Week 8, including on sensitive skin areas.
Clinical Trials Registration
Clinicaltrials.gov numbers: NCT05014568, NCT05032859.
Enhancing Clinical Practice
Clinical trials are vital for developing safe treatments. To make these findings practical, we introduce DocSym, an AI-driven platform that consolidates essential medical knowledge into one accessible resource.
Practical Solutions
- Streamlined Operations: Our mobile apps assist with scheduling, treatment monitoring, and telemedicine, simplifying patient care.
- Improved Workflows: AI technology helps clinics enhance efficiency, reduce paperwork, and improve patient outcomes.
Discover how we can support your practice at aidevmd.com.
